Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
Recent studies reveal immunotherapy failed to improve survival in small-cell lung cancer when combined with chemoradiation, while timing of immunotherapy after radiation therapy affects outcomes in non-small cell lung cancer patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07283939 |
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays |
RECRUITING | NA |
| NCT07091617 |
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer |
RECRUITING | NA |
| NCT06992427 |
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer |
RECRUITING | PHASE3 |
| NCT06931340 |
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial |
RECRUITING | PHASE3 |
| NCT06876714 |
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab |
RECRUITING | PHASE3 |
| NCT06686771 |
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer |
RECRUITING | PHASE3 |
| NCT06671912 |
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial |
SUSPENDED | PHASE3 |
| NCT06661720 |
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer |
RECRUITING | PHASE3 |
| NCT06632977 |
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial |
RECRUITING | PHASE2 |
| NCT06632327 |
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer |
RECRUITING | PHASE3 |
